Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
Michael Friedlander, Ursula Matulonis, Charlie Gourley, Andreas du Bois, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra, Daniela Matei, Vadim Shirinkin, Frederic Selle, Anitra Fielding, Elizabeth S Lowe, Emma L McMurtry, Stuart Spencer, Philip Rowe, Helen Mann, David Parry Show all
BRITISH JOURNAL OF CANCER | SPRINGERNATURE | Published : 2018
BACKGROUND: In Study 19, maintenance monotherapy with olaparib significantly prolonged progression-free survival vs placebo in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer. METHODS: Study 19 was a randomised, placebo-controlled, Phase II trial enrolling 265 patients who had received at least two platinum-based chemotherapy regimens and were in complete or partial response to their most recent regimen. Patients were randomised to olaparib (capsules; 400 mg bid) or placebo. We present long-term safety and final mature overall survival (OS; 79% maturity) data, from the last data cut-off (9 May 2016). RESULTS: Thirty-two patients (24%) received maintenance olapari..View full abstract
Related Projects (1)
This study was sponsored by AstraZeneca.